Medical equipment manufacturer Onkos Surgicals has launched its magnesium bone scaffolding technology GenVie.

It is clallegedly the first 510(k) cleared magnesium-based bone void filler in the orthopaedic marketplace.

GenVie, both injectable and mouldable, assists in bone repair and generation.

The product is applicable in surgically created osseous defects, as well as those created from traumatic injury to the bone.

Onkos Surgical CEO and co-founder Patrick Treacy said: “We are excited for the launch of GenVie as this product platform provides extraordinary strength, resorption, and handling profile that our customers are looking for. GenVie provides an elegant solution for use in certain tumour and complex revision cases and compliments our focused and innovative portfolio.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

This product is available through a private label distribution agreement with Bone Solutions. (OsteoCrete) announced last year.

The company claimed that the product offers a healing rate of 80% at twenty-six weeks in a preclinical model.

The launch of GenVie marks the first of several products that the company is planning to launch this year. It further expands the company’s reach in limb salvage procedures.

Founded in 2015, Onkos Surgical delivers implants and instruments to meet the needs of musculoskeletal tumour patients.